Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma

Bone Marrow Transplantation volume 32, pages 587–592 (2003)Cite this article

Summary:

The purpose of this study was to determine the effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. We performed a retrospective review of 67 patients newly diagnosed with multiple myeloma at Mayo Clinic and treated with a single regimen prior to stem cell transplantation between January of 2000 and September of 2001. Stem cells were collected from 24 patients who received thalidomide, 200 mg/day, with dexamethasone as initial therapy before stem cell collection. These patients were compared with 43 control patients seen during the same period who had received only one previous regimen before stem cell collection and transplantation. The cumulative thalidomide dose before stem cell collection was 17 000 mg over a median of four cycles (range, 2–7 cycles). The thalidomide and control groups were not significantly different in their baseline characteristics, number of stem cells collected, time to collection, or time to engraftment of neutrophils or platelet count of 50 000/μl. Time to platelet count of 20 000/μl was delayed by a median of 4 days (P=0.008), but platelet transfusion requirements did not differ (P=0.95). We concluded that thalidomide does not substantially affect peripheral cell mobilization or engraftment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myelome. N Engl J Med 1996; 335: 91–97.

    Article  CAS  Google Scholar 

  2. Rajkumar SV, Kyle RA . Angiogenesis in multiple myeloma. Semin Oncol 2001; 28: 560–564.

    Article  CAS  Google Scholar 

  3. Stirling D . Thalidomide: a novel template for anticancer drugs. Semin Oncol 2001; 28: 602–606.

    Article  CAS  Google Scholar 

  4. Rajkumar SV . Thalidomide in multiple myeloma. Oncology (Huntingt) 2000; 14 (Suppl. 13): 11–16.

    CAS  Google Scholar 

  5. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571.

    Article  CAS  Google Scholar 

  6. Rajkumar SV, Dispenzieri A, Fonseca R et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001; 15: 1274–1276.

    Article  CAS  Google Scholar 

  7. Weber DM, Rankin K, Gavino M et al. Thalidomide with dexamethasone for resistant multiple myeloma. Blood 2000; 96: 167a. (Abstr.).

    Google Scholar 

  8. Desikan RK, Jagannath S . Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions. Semin Oncol 2001; 28: 593–596.

    Article  CAS  Google Scholar 

  9. Goldschmidt H, Hegenbart U, Wallmeier M et al. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98: 736–744.

    Article  CAS  Google Scholar 

  10. Kroger N, Zeller W, Hassan HT et al. Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone. Ann Hematol 1998; 76: 257–262.

    Article  CAS  Google Scholar 

  11. Prince HM, Imrie K, Sutherland DR et al. Peripheral blood pregenitor cell collections in multiple myeloma: Predictors and management of inadequate collections. Br J Haematol 1996; 93: 142–145.

    Article  CAS  Google Scholar 

  12. Desikan KR, Jagannath S, Siegel D et al. Collection of more hematopoietic progenitor cells with large volume leukapheresis in patients with multiple myeloma. Leuk Lymphoma 1998; 28: 501–508.

    Article  CAS  Google Scholar 

  13. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825–831.

    Article  CAS  Google Scholar 

  14. Cappio FC, Cavo M, DeVincentiis A et al. Peripheral blood stem cell transplantation for the treatment of multiple myeloma: Biological and clinical implications. Haematologica 1996; 81: 356–375.

    CAS  PubMed  Google Scholar 

  15. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588–596.

    CAS  Google Scholar 

  16. Gertz MA, Lacy MQ, Inwards DJ et al. Factors influencing platelet recovery after blood cell transplantation in multiple myeloma. Bone Marrow Transplant 1997; 20: 375–380.

    Article  CAS  Google Scholar 

  17. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  18. Kyle RA, Rajkumar SV . Therapeutic application of thalidomide in multiple myeloma. Semin Oncol 2001; 28: 583–587.

    Article  CAS  Google Scholar 

  19. Tosi P, Ronconi S, Zamagni E et al. Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. Haematologica 2001; 86: 409–413.

    CAS  Google Scholar 

  20. Rajkumar SV, Fonseca R, Dispenzieri A et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 2000; 75: 897–901.

    Article  CAS  Google Scholar 

  21. Hideshima T, Chauhan D, Podar K et al. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001; 28: 607–612.

    Article  CAS  Google Scholar 

  22. D'Amato RJ, Lentzsch S, Anderson KC et al. Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin Oncol 2001; 28: 597–601.

    Article  CAS  Google Scholar 

  23. Rajkumar SV, Witzig TE . A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 2000; 26: 351–362.

    Article  CAS  Google Scholar 

  24. Kroger N, Zeller W, Hassan HT et al. Difference between expression of adhesion molecules on CD34+ cells from bone marrow and G-CSF-stimulated peripheral blood. Stem Cells 1998; 16: 49–53.

    Article  CAS  Google Scholar 

  25. Nogueira AC, Neubert R, Helge H et al. Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sci 1994; 55: 77–92.

    Article  CAS  Google Scholar 

  26. Geitz H, Handt S, Zwingenberger K . Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996; 31: 213–221.

    Article  CAS  Google Scholar 

  27. Lichterfeld M, Martin S, Burkly L et al. Mobilization of CD34+ haematopoietic stem cells is associated with a functional inactivation of the integrin very late antigen 4. Br J Haematol 2000; 110: 71–81.

    Article  CAS  Google Scholar 

  28. Byrne JL, Russell NH . Peripheral blood stem cell transplants. J Clin Pathol 1998; 51: 351–355.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA

    I M Ghobrial, A Dispenzieri, D A Gastineau, S V Rajkumar, M Q Lacy, T E Witzig, M R Litzow, S Hayman & M A Gertz

  2. Division of Transfusion Medicine, Mayo Clinic, Rochester, MN, USA

    K L Bundy, D A Gastineau & C G Pribula

  3. Division of Biostatistics, Mayo Clinic, Rochester, MN, USA

    T M Therneau

  4. Section of Pharmacy, Mayo Clinic, Rochester, MN, USA

    B R Christensen

Authors
  1. I M Ghobrial
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Dispenzieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K L Bundy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D A Gastineau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S V Rajkumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T M Therneau
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Q Lacy
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T E Witzig
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M R Litzow
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. B R Christensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S Hayman
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. C G Pribula
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M A Gertz
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Presented as a Poster presentation at the 38th Annual Meeting of the American Society of Clinical Oncology, May 18–21, 2002. Supported in part by the Hematologic Malignancies Fund, Mayo Clinic.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ghobrial, I., Dispenzieri, A., Bundy, K. et al. Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. Bone Marrow Transplant 32, 587–592 (2003). https://doi.org/10.1038/sj.bmt.1704173

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704173

Keywords

This article is cited by

Search

Advanced search

Quick links